We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
Read MoreHide Full Article
Humana Inc. (HUM - Free Report) recently inked a value-based care agreement with the Massachusetts-based kidney care management company, Interwell Health. The partnership targets to offer enhanced care mainly to HUM’s Medicare Advantage HMO and PPO members residing across 13 states and suffering from chronic kidney disease (CKD) or end-stage kidney disease (ESKD).
The abovementioned states refer to Arizona, Arkansas, Colorado, Kansas, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, and West Virginia. The specified Humana members can avail the holistic care and specialized resources of Interwell, which comprise access to 1,700 network nephrologists, renal care coordinators and in-home virtual assistance from dietitians, nurses, social workers, pharmacists, and care coordinators.
Value-based care models put focus on coordinated effort to bring about improved health outcomes as well as lower the costs of care. Therefore, the recent tie-up is likely to equip Humana to better address kidney-related issues of its Medicare Advantage customers. And Interwell, backed by its credible nephrologists’ network stretched across the United States, seems to be the apt partner to complement HUM’s endeavor.
The latest agreement also seems to be a time opportune one, considering a substantial portion of American adults suffering from CKD. The disease, if not detected at the right time, can lead to kidney failure, following which dialysis or kidney transplant becomes necessary.
The idea of integrating the benefit of extensive kidney-related care from Interwell as part of its Medicare Advantage plans is likely to lure more customers to opt for such plans and contribute to the customer base of Humana. Needless to say, an expanding membership provides an impetus to a health insurer’s premiums, which are the most significant contributor to its top line. Premiums from the Medicare business of HUM rose 14.3% year over year in the first half of 2023. Management anticipates individual Medicare Advantage business to witness minimum growth of 825,000 this year.
Earlier as well, Humana had resorted to tie-ups with kidney care providers to effectively cater to its members' healthcare needs. The partnership with the comprehensive kidney health management program, REACH Kidney Care, aimed to address kidney-related issues of eligible Medicare Advantage and Commercial members of Humana across four U.S. states, which were Alabama, North Carolina, South Carolina, and Tennessee. The health insurer also formed an alliance with the Kidney Health Management solution provider, Healthmap Solutions, in a bid to cater to the kidney-related issues of HUM’s Medicare Advantage and Commercial members across Florida.
Shares of Humana have declined 2.8% in a year compared with the industry’s 9.3% fall. HUM currently carries a Zacks Rank #3 (Hold).
Encompass Health’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and missed the mark once, the average surprise being 14.04%. The Zacks Consensus Estimate for EHC’s 2023 earnings suggests 19% growth from the year-ago reported figure.
The consensus estimate for EHC’s 2023 earnings has moved 6.3% north in the past 30 days. Shares of Encompass Health have gained 36.8% in the past year.
ANI Pharmaceuticals’ earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 91.56%. The Zacks Consensus Estimate for ANIP’s 2023 earnings is pegged at $3.73 per share, which indicates nearly a three-fold increase from the prior-year reported figure. The same for revenues indicates growth of 39.6% from the year-ago reported figure.
The consensus estimate for ANIP’s 2023 earnings has moved 10% north in the past 30 days. Shares of ANIP Pharmaceuticals have gained 68.9% in a year.
Ensign Group’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, matched the mark once and missed the same on the remaining one occasion, the average surprise being 0.88%. The Zacks Consensus Estimate for ENSG’s 2023 earnings indicates a rise of 13.8%, while the same for revenues suggests an improvement of 22.7% from the corresponding year-ago reported estimates.
The Zacks Consensus Estimate for ENSG’s 2023 earnings has moved 0.2% north in the past 60 days. Shares of Ensign Group have rallied 7.8% in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
Humana Inc. (HUM - Free Report) recently inked a value-based care agreement with the Massachusetts-based kidney care management company, Interwell Health. The partnership targets to offer enhanced care mainly to HUM’s Medicare Advantage HMO and PPO members residing across 13 states and suffering from chronic kidney disease (CKD) or end-stage kidney disease (ESKD).
The abovementioned states refer to Arizona, Arkansas, Colorado, Kansas, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, and West Virginia. The specified Humana members can avail the holistic care and specialized resources of Interwell, which comprise access to 1,700 network nephrologists, renal care coordinators and in-home virtual assistance from dietitians, nurses, social workers, pharmacists, and care coordinators.
Value-based care models put focus on coordinated effort to bring about improved health outcomes as well as lower the costs of care. Therefore, the recent tie-up is likely to equip Humana to better address kidney-related issues of its Medicare Advantage customers. And Interwell, backed by its credible nephrologists’ network stretched across the United States, seems to be the apt partner to complement HUM’s endeavor.
The latest agreement also seems to be a time opportune one, considering a substantial portion of American adults suffering from CKD. The disease, if not detected at the right time, can lead to kidney failure, following which dialysis or kidney transplant becomes necessary.
The idea of integrating the benefit of extensive kidney-related care from Interwell as part of its Medicare Advantage plans is likely to lure more customers to opt for such plans and contribute to the customer base of Humana. Needless to say, an expanding membership provides an impetus to a health insurer’s premiums, which are the most significant contributor to its top line. Premiums from the Medicare business of HUM rose 14.3% year over year in the first half of 2023. Management anticipates individual Medicare Advantage business to witness minimum growth of 825,000 this year.
Earlier as well, Humana had resorted to tie-ups with kidney care providers to effectively cater to its members' healthcare needs. The partnership with the comprehensive kidney health management program, REACH Kidney Care, aimed to address kidney-related issues of eligible Medicare Advantage and Commercial members of Humana across four U.S. states, which were Alabama, North Carolina, South Carolina, and Tennessee. The health insurer also formed an alliance with the Kidney Health Management solution provider, Healthmap Solutions, in a bid to cater to the kidney-related issues of HUM’s Medicare Advantage and Commercial members across Florida.
Shares of Humana have declined 2.8% in a year compared with the industry’s 9.3% fall. HUM currently carries a Zacks Rank #3 (Hold).
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks in the Medical space are Encompass Health Corporation (EHC - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and The Ensign Group, Inc. (ENSG - Free Report) . While Encompass Health currently sports a Zacks Rank #1 (Strong Buy), ANI Pharmaceuticals and Ensign Group carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Encompass Health’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and missed the mark once, the average surprise being 14.04%. The Zacks Consensus Estimate for EHC’s 2023 earnings suggests 19% growth from the year-ago reported figure.
The consensus estimate for EHC’s 2023 earnings has moved 6.3% north in the past 30 days. Shares of Encompass Health have gained 36.8% in the past year.
ANI Pharmaceuticals’ earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 91.56%. The Zacks Consensus Estimate for ANIP’s 2023 earnings is pegged at $3.73 per share, which indicates nearly a three-fold increase from the prior-year reported figure. The same for revenues indicates growth of 39.6% from the year-ago reported figure.
The consensus estimate for ANIP’s 2023 earnings has moved 10% north in the past 30 days. Shares of ANIP Pharmaceuticals have gained 68.9% in a year.
Ensign Group’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, matched the mark once and missed the same on the remaining one occasion, the average surprise being 0.88%. The Zacks Consensus Estimate for ENSG’s 2023 earnings indicates a rise of 13.8%, while the same for revenues suggests an improvement of 22.7% from the corresponding year-ago reported estimates.
The Zacks Consensus Estimate for ENSG’s 2023 earnings has moved 0.2% north in the past 60 days. Shares of Ensign Group have rallied 7.8% in the past year.